AgingResearch.NewsJoin free

Seaport Therapeutics

CompanyUnited States

Seaport Therapeutics develops one asset, in phase 2 (GlyphAgo in generalized anxiety disorder). Mostly small molecule; based in the United States.

1
Asset
Furthest stage
Phase 2
0
Trials
0
Signals

Pipeline

1

  • GlyphAgo

    Modulates central neurotransmission to treat anxiety and sleep disturbance

    Phase 2, Small molecule, generalized anxiety disorder, sleep disturbance

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Similar companies2

Intelligence